skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Efficacy and patient tolerability of travoprost BAK-free solution in patients with open-angle glaucoma and ocular hypertension

Review

(1675) Views  (646) Full article downloads

Authors: Sophia K Mirza, Sandra M Johnson

Published Date July 2010 Volume 2010:4 Pages 877 - 888
DOI: http://dx.doi.org/10.2147/OPTH.S6292

Sophia K Mirza, Sandra M Johnson

Department of Ophthalmology, University of Virginia, Charlottesville, Virginia, USA

Abstract: The medical treatment of glaucoma has evolved significantly over the past several decades. The main driving forces behind this evolution are the safety profiles and efficacy of these medications. Prostaglandin (PG) analogs are shown to be superior to older drugs in both efficacy and tolerability. Though there are much fewer side effects that manifest after using PG analogs, the adherence and compliance to medication regimens are surprisingly lower than expected. A commonly sited reason is the ocular irritation and inflammation with these medications. Much of this inflammation can be attributed to the preservative, benzalkonium chloride (BAK). The chronic clinical and subclinical inflammation becomes increasingly detrimental when filtration surgery fails from bleb fibrosis secondary to this hypercellularity. A BAK-free formulation of a PG analog recently became available. BAK-free travoprost is reviewed here. It has demonstrated equal efficacy and less ocular surface toxicity than its preserved counterparts. It is expected to serve as an instrumental resource in managing ocular hypertension and glaucoma in patients who demonstrate significant sensitivity to BAK. More randomized, controlled, double-blind studies are encouraged to evaluate its improved safety and tolerability.

Keywords: glaucoma, benzalkonium chloride, Travatan Z, sofZia






Readers of this article also read:

Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis
Measurement of treatment compliance using a medical device for glaucoma patients associated with intraocular pressure control: a survey
Effect of travoprost on 24-hour intraocular pressure in normal tension glaucoma
Clinical imaging and high-resolution ultrasonography in melanocytoma management
Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients
Ocular hypotensive effect, preservation of visual fields, and safety of adding dorzolamide to prostaglandin therapy for twelve months
First experience with BAK-free travoprost 0.004% in topical glaucoma medication
Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from ß-blockers and prostaglandin analogs
Sustained intraocular pressure reduction throughout the day with travoprost ophthalmic solution 0.004%
Efficacy and safety of travoprost 0.004%/timolol 0.5% fixed combination as transition therapy in patients previously on prostaglandin analog monotherapy